Literature DB >> 21111397

Routine use of abdominopelvic ultrasonography in severe postpartum hemorrhage: retrospective evaluation in 125 patients.

Ruben Lousquy1, Olivier Morel, Philippe Soyer, Cécile Malartic, Etienne Gayat, Emmanuel Barranger.   

Abstract

OBJECTIVE: The purpose of this study was to analyze the potential of abdominopelvic ultrasonography at the initial examination in women with severe postpartum hemorrhage. STUDY
DESIGN: One hundred twenty-five women were included in the study. The therapeutic approaches that were performed to stop the bleeding were evaluated for each category of ultrasonographic finding.
RESULTS: Seventy-one women (56.8%) had normal ultrasonography; 30 women (24%) had echogenic endometrial lining; 17 women (13.6%) had echogenic intrauterine mass, and 7 women (5.6%) had abdominopelvic free fluid effusion. Medical therapies allowed the bleeding to stop in 90.1% of women with normal ultrasonography, in 66.6% of women with echogenic endometrial lining, and in 29.4% of women with echogenic intrauterine mass. Pelvic embolization and surgery were performed less frequently in women who had normal ultrasonography results (9.9%) than in women with abnormal ultrasonography results (46.8%; P < .0001).
CONCLUSION: A normal abdominopelvic ultrasonography is associated with a favorable outcome and can be considered to be a predictor for the effectiveness of conservative, noninvasive therapeutic approaches.
Copyright © 2011 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 21111397     DOI: 10.1016/j.ajog.2010.10.003

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  1 in total

1.  Postpartum haemorrhage in Canada and France: a population-based comparison.

Authors:  Marie-Pierre Bonnet; Olga Basso; Marie-Hélène Bouvier-Colle; Corinne Dupont; René-Charles Rudigoz; Rebecca Fuhrer; Catherine Deneux-Tharaux
Journal:  PLoS One       Date:  2013-06-24       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.